New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:05 EDTHRC, BAXHill-Rom CFO Saccaro to leave company to re-join Baxter
Hill-Rom (HRC) said in a filing that on July 1, Jay Saccaro, CFO of the corporation, informed the Corporation that he was resigning to accept a position with his previous employer, Baxter International (BAX), as CFO-designate of the post-spin-off company. Saccaro ceased to be the principal financial officer of the corporation as of July 3. As of July 3, Michael Macek, the Vice President and Treasurer of the Corporation, assumed the additional duties of Interim CFO and become the principal financial officer of the corporation pending the search for Saccaro’s replacement. Macek was elected Treasurer in March 2011. Prior to such date, he held the position of Executive Director, Treasury for Hill-Rom since 2008, and a series of financial positions with Hill-Rom since 2005. He also served as the corporation’s Interim CFO from July 2013 through December 2013.
News For HRC;BAX From The Last 14 Days
Check below for free stories on HRC;BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
11:31 EDTHRCHill-Rom announces seven-year, sole-source contract with Providence Health
Subscribe for More Information
September 17, 2014
08:44 EDTBAXJPMorgan biotech analysts hold an analyst/industry conference call
Subscribe for More Information
September 15, 2014
09:16 EDTBAXOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTBAXBaxter announces FDA approval for RIXUBIS
(BAX) announced that the U.S. Food and Drug Administration has approved RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX approved for routine prophylaxis and control of bleeding episodes in the U.S. for adults living with this chronic condition. The approval is based on the results of a clinical trial investigating the efficacy and safety of RIXUBIS among 23 previously-treated male patients less than 12 years of age with severe or moderately severe hemophilia B. There were no reports of inhibitor development, no severe allergic reactions, and no thrombotic or treatment-related adverse events among the study participants. Baxter’s application for marketing approval for RIXUBIS for adults and pediatric patients is currently under review in the EU, with a regulatory decision expected later this year. The treatment also recently gained regulatory approval in Australia.
September 12, 2014
20:32 EDTBAXFDA approves Baxter's HYQVIA for treatment of primary immunodeficiency
Subscribe for More Information
September 11, 2014
08:15 EDTBAXBaxter says separation on track for mid-2015, new company to be called 'Baxalta'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use